Biotech is an area in science people didn’t know much about. But recent discoveries in genetics have put biotech on the map again. Large business parks house companies that specialise in biotech, and they keep growing. Seattle genetics is one such company. Steering this ship is their CEO Clay Siegall.
Making a Breakthrough in Research
Seattle Genetics mainly work with human antibodies. They perform research via shaping and modifying them to be used for medicinal purposes. The scientists are trying to find new ways natural antibodies can help people fight diseases. One of the biggest fights on their hands is cancer. If there could be a possibility of therapy that would destroy cancerous cells from within, it would be a massive breakthrough.
The company now provides around 900 jobs, and Clay Siegall proudly reveals their plans on expanding to add 200 more people to their roster. Their biggest market success is also their biggest health success. Adcetris is a drug that helps with Hodgkin lymphoma treatment. It’s currently in testing stages. But sales could take off quickly if the tests prove to be positive and successful.
Clay Siegall is ambitious and passionate about this line of work. He is not afraid of taking risks and in this 10 billion-dollar industry that is no small feat. He wants to make cancer drugs more accessible for people and develop new medicines to kill more aggressive forms of this disease. His ambitions are reflected in his leadership. Open and honest, he is a pleasant person to spend time with. He has the know-how and the business smarts that are crucial for this industry.
The Positive and the Smart
The market is becoming more demanding and competitive, so Clay Siegall often finds himself making quick decisions that can cost the company millions of dollars. However, if it helps people, he is not afraid to do it.
New research in cancer therapy is also crucial. Clay Siegall’s company is not yet breaking down any doors, but they are making progress. The combination of different drugs could help to create a cancer treatment that is less invasive and doesn’t leave people with the side-effects of nausea, weakness and fatigue.
He doesn’t take no for an answer and knows that you cannot win if you don’t lose from time to time. He has entrepreneur skills and the enthusiasm to keep going. He knows the market and follows his competitors’ work to see the progress drug companies are trying to make where cancer is concerned.